MA53739A - Composition et son utilisation pour le traitement de la maladie de parkinson et de troubles apparentés - Google Patents
Composition et son utilisation pour le traitement de la maladie de parkinson et de troubles apparentésInfo
- Publication number
- MA53739A MA53739A MA053739A MA53739A MA53739A MA 53739 A MA53739 A MA 53739A MA 053739 A MA053739 A MA 053739A MA 53739 A MA53739 A MA 53739A MA 53739 A MA53739 A MA 53739A
- Authority
- MA
- Morocco
- Prior art keywords
- parkinson
- disease
- treatment
- composition
- related disorders
- Prior art date
Links
- 208000018737 Parkinson disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/428—Thiazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Hospice & Palliative Care (AREA)
- Otolaryngology (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862735997P | 2018-09-25 | 2018-09-25 | |
| US201862785606P | 2018-12-27 | 2018-12-27 | |
| US201862785605P | 2018-12-27 | 2018-12-27 | |
| US201862785602P | 2018-12-27 | 2018-12-27 | |
| US201962787614P | 2019-01-02 | 2019-01-02 | |
| US201962817274P | 2019-03-12 | 2019-03-12 | |
| US201962840539P | 2019-04-30 | 2019-04-30 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA53739A true MA53739A (fr) | 2021-12-29 |
Family
ID=69949689
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA053739A MA53739A (fr) | 2018-09-25 | 2019-09-24 | Composition et son utilisation pour le traitement de la maladie de parkinson et de troubles apparentés |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20210338652A1 (fr) |
| EP (1) | EP3856168A4 (fr) |
| JP (1) | JP2022502479A (fr) |
| KR (1) | KR20210107621A (fr) |
| CN (1) | CN113164424A (fr) |
| AU (1) | AU2019346543A1 (fr) |
| BR (1) | BR112021008087A2 (fr) |
| CA (1) | CA3121184A1 (fr) |
| IL (1) | IL282562A (fr) |
| MA (1) | MA53739A (fr) |
| WO (1) | WO2020068832A1 (fr) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3615024B1 (fr) | 2017-04-24 | 2026-02-18 | Alto Neuroscience, Inc. | Compositions comprenant du pramipexole et d'un antagoniste 5ht3 pour utilisation dans le traitement de la dépression |
| CN111588692B (zh) * | 2020-05-23 | 2022-11-22 | 常州市第四制药厂有限公司 | 盐酸普拉克索口服溶液 |
| IL321446A (en) | 2022-12-12 | 2025-08-01 | Tiefenbacher Alfred E Gmbh & Co Kg | Fixed-dose combination including netopitant and flunosterone |
| EP4385497A1 (fr) * | 2022-12-12 | 2024-06-19 | Alfred E. Tiefenbacher (GmbH & Co. KG) | Combinaison de doses fixes sans antioxydant de nétupitant et de palonosétron |
| EP4385500A1 (fr) * | 2022-12-12 | 2024-06-19 | Alfred E. Tiefenbacher (GmbH & Co. KG) | Combinaison de doses fixes comprenant du nétupitant et du palonosétron |
| WO2024126408A1 (fr) | 2022-12-12 | 2024-06-20 | Alfred E. Tiefenbacher (Gmbh & Co. Kg) | Association de dose fixe sans antioxydant de netupitant et de palonosétron |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0942732B1 (fr) * | 1996-12-02 | 2004-11-17 | MERCK SHARP & DOHME LTD. | Utilisation d'antagonistes du recepteur nk-1 dans le traitement des diskynesies |
| JP2004523543A (ja) * | 2001-02-15 | 2004-08-05 | ニューロサーチ、アクティーゼルスカブ | 神経栄養活性を有する化合物とドパミン活性を増加させる化合物の組み合わせ作用によるパーキンソン病の治療法 |
| AU2015213396B2 (en) * | 2009-09-18 | 2018-02-15 | Chase Pharmaceuticals Corporation | Method and composition for treating Alzheimer-type dementia |
| EA031156B1 (ru) * | 2010-12-16 | 2018-11-30 | Суновион Фармасьютикалз Инк. | Сублингвальные пленки |
| AU2013344388A1 (en) * | 2012-11-19 | 2015-07-09 | Braeburn Pharmaceuticals, Inc. | Implantable drug delivery compositions and methods of treatment thereof |
| WO2018039159A1 (fr) * | 2016-08-22 | 2018-03-01 | Chase Pharmaceuticals Corporation | Combinaison d'antagoniste de m2 muscarinique |
| MX389282B (es) * | 2017-03-27 | 2025-03-20 | Chase Therapeutics Corp | Composiciones y métodos para tratar sinucleinopatías. |
| JP7158425B2 (ja) * | 2017-06-30 | 2022-10-21 | チェイス セラピューティクス コーポレイション | Nk-1アンタゴニスト組成物およびうつ病の処置における使用法 |
-
2019
- 2019-09-24 AU AU2019346543A patent/AU2019346543A1/en not_active Abandoned
- 2019-09-24 EP EP19864237.3A patent/EP3856168A4/fr not_active Withdrawn
- 2019-09-24 CA CA3121184A patent/CA3121184A1/fr active Pending
- 2019-09-24 JP JP2021536745A patent/JP2022502479A/ja active Pending
- 2019-09-24 US US17/279,644 patent/US20210338652A1/en not_active Abandoned
- 2019-09-24 WO PCT/US2019/052705 patent/WO2020068832A1/fr not_active Ceased
- 2019-09-24 MA MA053739A patent/MA53739A/fr unknown
- 2019-09-24 KR KR1020217012445A patent/KR20210107621A/ko not_active Ceased
- 2019-09-24 CN CN201980077431.9A patent/CN113164424A/zh active Pending
- 2019-09-24 BR BR112021008087-2A patent/BR112021008087A2/pt unknown
-
2021
- 2021-04-22 IL IL282562A patent/IL282562A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2022502479A (ja) | 2022-01-11 |
| WO2020068832A1 (fr) | 2020-04-02 |
| AU2019346543A1 (en) | 2021-05-20 |
| KR20210107621A (ko) | 2021-09-01 |
| BR112021008087A2 (pt) | 2021-08-03 |
| EP3856168A4 (fr) | 2022-07-06 |
| US20210338652A1 (en) | 2021-11-04 |
| IL282562A (en) | 2021-06-30 |
| CA3121184A1 (fr) | 2020-04-02 |
| EP3856168A1 (fr) | 2021-08-04 |
| CN113164424A (zh) | 2021-07-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA53739A (fr) | Composition et son utilisation pour le traitement de la maladie de parkinson et de troubles apparentés | |
| MA52631A (fr) | Compositions et méthodes pour le traitement de la maladie de parkinson | |
| MA54792A (fr) | Compositions et méthodes pour le traitement de la maladie de parkinson | |
| EP3820537A4 (fr) | Vecteurs de thérapie génique pour le traitement de la maladie de danon | |
| MA49402A (fr) | Polynucléotides aadc pour le traitement de la maladie de parkinson | |
| MA53661A (fr) | Agonistes du récepteur farnésoïde x pour le traitement d'une maladie | |
| MA49279A (fr) | Compositions d'anticorps optimisées pour le traitement de troubles oculaires | |
| EP3704108A4 (fr) | Composés et compositions pour le traitement de troubles hématologiques | |
| EP3790867A4 (fr) | Inhibiteurs de kdm1a pour le traitement d'une maladie | |
| EP3405215A4 (fr) | Méthodes destinées au traitement de la maladie de danon et d'autres troubles liés à l'autophagie | |
| EP3528852A4 (fr) | Méthodes et compositions pour le traitement de la maladie de fabry | |
| EP3906043A4 (fr) | Procédés et compositions pour le traitement de la maladie de fabry | |
| EP3737361A4 (fr) | Inhibiteurs de la dihydrocéramide désaturase pour le traitement d'une maladie | |
| EP3924371A4 (fr) | Vecteurs de thérapie génique pour le traitement de la maladie de danon | |
| EP3927706A4 (fr) | Composés d'imidazopyridinyle et leur utilisation pour le traitement de troubles prolifératifs | |
| MA55148A (fr) | Composés d'aryl-aniline et d'hétéroaryl-aniline pour le traitement de marques de naissance | |
| EP3655404A4 (fr) | Composés et leur utilisation pour le traitement d'infections microbiennes | |
| EP3802568A4 (fr) | Agents thérapeutiques peptidiques pour le traitement de la maladie d'alzheimer et d'états apparentés | |
| EP3654961A4 (fr) | Méthodes et compositions pour le traitement de la douleur à l'aide de la capsaïcine | |
| MA55141A (fr) | Composés cyanoaryl-aniline pour le traitement d'affections de la peau | |
| EP3852722A4 (fr) | Compositions et méthodes pour le traitement de la maladie de parkinson | |
| EP3806865A4 (fr) | Tétracycline modifiée pour le traitement des troubles de l'usage de l'alcool, de la douleur et d'autres troubles impliquant des processus inflammatoires potentiels | |
| EP3628008A4 (fr) | Compositions et méthodes pour le traitement de la maladie d'alzheimer | |
| EP4052694A4 (fr) | Composition de gouttes oculaires pour la prévention ou le traitement d'une maladie oculaire | |
| MA54530A (fr) | Schémas posologiques pour l'utilisation de ly3154207 dans le traitement de troubles du système nerveux central dopaminergiques |